4th ADC Linker and Conjugation Summit Revere Hotel Boston Common, Boston

ADC innovation is accelerating beyond traditional cytotoxins into dual-payload constructs, high-DAR species, degrader-antibody conjugates, and next-generation modalities. However, this rapid evolution is placing unprecedented pressure on linker architecture and conjugation chemistry to control stability, reduce off-target toxicity, overcome tumor resistance, and maintain manufacturability.

To meet these challenges head on, the 4th ADC Linker and Conjugation Summit offers a highly technical, deeply curated environment built specifically for specialists working at the cutting edge of ADC chemistry. At this summit, you aren’t lost in a crowd, you’re surrounded by peers who share the same job titles, scientific focus, and day-to-day challenges. Every session is built for specialists, every conversation is relevant, and every detail is designed to advance real chemistry solutions.

Over three focused days, 80+ ADC chemists, protein engineers, and translational scientists will dissect the core chemistry questions shaping next generation ADC performance. With 20+ expert-led case studies from leading biopharma and biotech innovators, you’ll gain actionable insights to engineer homogeneous ADCs, prevent premature payload release, enable orthogonal dual payload systems, mitigate hydrophobicity driven aggregation, and integrate predictive modeling into platform design.